Validity

In most systems, a patent is valid for 20 years from the filing date of the patent application. Patents are granted with a presumption of validity but no patent is safe from being challenged and declared (partially) invalid by national courts or, in the case of European patents, revoked by the European Patent Office. Often, a claim of invalidity of a patent is a reaction to an action of the patentee, in particular an infringement action.

Biologics, Inventive step, Italy, Validity

(Trevisan & Cuonzo)/

By ruling of 10 July 2012, the Court of Turin decided in the first instance an infringement action filed by Italian company Novamont against German and French companies Biotec and Biosphère, for the alleged infringement of three Novamont patents concerning starch based plastic materials used in the production of biodegradable shoppers. The Court denied the…

Case Law, Inventive step, Italy, Validity

(Trevisan & Cuonzo)/

The District Court of Turin rejected Merck’s requests for a preliminary injunction, finding lack of inventive step of the claimed co-formulation of dorzolamid and timolol based on a prima facie assessment following the problem solution approach of the EPO Boards of Appeal. Click here  for the full text of this case. A summary of this…

Countries, Denmark, EPC, Finland, Germany, Injunction, Inventive step, Netherlands, Opposition, Revocation, United Kingdom, Validity

(Hoffmann Eitle)/

The interesting six-jurisdiction patent case between two of the world’s leading enzyme manufacturers, the Danish companies Danisco A/S (now part of DuPont) and Novozymes A/S has already been subject to earlier blogs both here and several times on EPLAW and PatLit. To recap the story briefly, Novozymes started the proceedings by applying for a preliminary…

(Indirect) infringement, Chemical Engineering, EPC, Exceptions to patentability, France, Inventive step, Novelty, Revocation, Second Medical Use, Sufficiency of disclosure, Validity

(Véron & Associés)/

On 20 March 2012, the Tribunal de Grande Instance of Paris rendered its decision in the case relating to raloxifene, a molecule useful for treating or preventing osteoporosis in post-menopausal women, opposing Teva to Eli Lilly. This decision raises many questions, first concerning drug patents in particular (patentability of second medical use, patentability of the resolution of…

Italy, Novelty, Validity

(Trevisan & Cuonzo)/

By decision of 23 March 2012, the Supreme Court decided a case between two competitors in the field of steel products and machinery, concerning in particular the alleged infringement of two Italian patents covering a winding up mechanism for steel wire. The alleged infringer had counterclaimed invalidity based on prior disclosure, claiming in particular that…

Denmark, Inventive step, Novelty, Validity

(Bugge Valentin)/

In a recent decision (16.5.2012) the Supreme Court in Denmark has ruled on the requirement of creative step that applies to Danish utility models and serves the same purpose as inventive step in respect of patents. The utility model-in-suit had been invalidated by the Danish Patent Office and that decision was upheld by the Maritime…

Case Law, Electrical Engineering, Germany, Inventive step, Validity

(Hoffmann Eitle)/

When seeking to improve a data structure prescribed in an international standard, the skilled person would consider mechanisms already described in the standard when solving the identified technical problem. If the standard provides a manageable number of possible solutions, each having specific advantages and disadvantages, this provides an incentive to take each of the solutions…